呼吸器内科 論文(2021年)
英語論文
1: Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Endo M, Kiyohara Y, Yasui H, Niwakawa M, Takahashi T. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs. 2021 Dec;39(6):1716-1723.
2: Kobayashi H, Wakuda K, Naito T, Mamesaya N, Omori S, Ono A, Kenmotsu H, Murakami H, Endo M, Harada H, Gon Y, Takahashi T. Chemoradiotherapy for limited- stage small-cell lung cancer and interstitial lung abnormalities. Radiat Oncol. 2021 Mar 17;16(1):52.
3: Takinami M, Ono A, Moriguchi M, Takahashi T. Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts. Jpn J Clin Oncol. 2021 Apr 1;51(4):666-667.
4: Kenmotsu H, Notsu A, Mori K, Omori S, Tsushima T, Satake Y, Miki Y, Abe M, Ogiku M, Nakamura T, Takagi M, Ochiai H, Yasui H, Takahashi T. Cumulative incidence of venous thromboembolism in patients with advanced cancer in prospective observational study. Cancer Med. 2021 Feb;10(3):895-904.
5: Miyawaki T, Wakuda K, Kenmotsu H, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Naito T, Murakami H, Notsu A, Mori K, Harada H, Endo M, Ohde Y, Takahashi K, Takahashi T. Proposing synchronous oligometastatic non-small-cell lung cancer based on progression after first-line systemic therapy. Cancer Sci. 2021 Jan;112(1):359-368.
6: Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Shimizu T, Gon Y, Takahashi T. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors. Jpn J Clin Oncol. 2021 Dec 1;51(12):1736-1743.
7: Takahashi T, Umeguchi H, Tateishi A, Yoshida T, Motoi N, Ohe Y. Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib. Lung Cancer. 2021 Jan;151:1-4.
8: Nishioka N, Naito T, Notsu A, Mori K, Kodama H, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Murakami H, Takayama K, Takahashi T. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non-small cell lung cancer. Cancer Med. 2021 Jan;10(1):247-256.
9: Kodama H, Kenmotsu H, Kawabata T, Notsu A, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Takahashi T. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation. Cancer Med. 2021 Nov;10(21):7503-7513.
10: Kodama H, Wakuda K, Yabe M, Nishioka N, Miyawaki E, Miyawaki T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non- small cell lung carcinoma. Invest New Drugs. 2021 Apr;39(2):571-577.
11: Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Invest New Drugs. 2021 Dec;39(6):1732-1741.
12: Inoue H, Ono A, Kawabata T, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Wakuda K, Kenmotsu H, Naito T, Murakami H, Yasui K, Ogawa H, Onoe T, Endo M, Harada H, Takahashi T. Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer. Invest New Drugs. 2021 Jun;39(3):899.
13: Miyawaki T, Kenmotsu H, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Ko R, Wakuda K, Ono A, Naito T, Murakami H, Mori K, Harada H, Endo M, Takahashi K, Takahashi T. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study. BMC Cancer. 2021 Nov 19;21(1):1247
14: Wakuda K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Mamesaya N, Kawamura T, Kobayashi H, Omori S, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Endo M, Gon Y, Takahashi T. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression. Lung Cancer. 2021 Jan;151:60-68.
15: Mamesaya N, Muramatsu K, Yabe M, Kodama H, Nishioka N, Miyawaki T, Miyawaki E, Kobayashi H, Omori S, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Harada H, Sugino T, Shimizu T, Gon Y, Takahashi T. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non- small cell lung cancer receiving chemoradiotherapy. Int J Clin Oncol. 2021 Apr;26(4):659-669.
16：Akamatsu H, Murakami H, Harada H et al. Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. J Thorac Oncol 2021; 16: 1745-1752.
17：Murakami H, Horinouchi H, Harada H et al. Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study. Lung Cancer 2021; 165: 152-163.
18：Ono A, Murakami H, Seto T et al. Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study. Drugs R D 2021; 21: 65-78.